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Breast cancer is prevailing as the most diagnosed
cancer in women. Obesity and its co-morbidities,
including type-II diabetes, are increasing to epidemic
proportions.
A pathological link between obesity, breast cancer risk
and mortality has been established recently.
Insulin resistance has been closely associated with
obesity. It is considered a pre-stage of type 2 diabetes
and is characterised by chronic high circulating levels
of insulin.
Previously we have demonstrated the ability of high
insulin levels to differentially activate insulin receptor,
PI3- kinase and MAP-kinase cell signalling pathways
in MDA-MB 231 human breast cancer cells and in
MCF-10a human normal breast epithelial cells in
addition to increase cell proliferation in MCF-10a cells.
We here demonstrate changes in gene expression
profiles after treatment of both cell lines with 100 nM
insulin for 1 h.
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Objective
To examine the effects of high insulin levels (100
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Detailed Results
High insulin levels increased expression of genes
involved in cell cycle control (e.g. cyclin E1) and DNA
damage repair (e.g. ATM) in MDA-MB 231 cells and in
MCF-10a cells (e.g. CDC25a).
Expression of genes responsible for mediating
apoptosis and cell senescence (e.g. APAF, BAD, bcl-
X) was decreased after insulin treatment in MDA-MB
231 cells but the expression of the same group of
genes did not change in MCF-10a cells.
High insulin levels increased expression of genes
encoding for signal transduction molecules (e.g.
AKT1) and transcription factors (e.g. FOS, JUN,
MYC), and of genes responsible for invasion and
metastasis (e.g. MMP2) in MCF-10a cells whereas
gene expression of the same groups of genes did not
change or was decreased in MDA-MB 231 cells.
These results suggest a role for insulin resistance in
breast cancer initiation and progression, aggravating
the potential of breast cancer cells to evade apoptosis,
to metastasise and may promote carcinogenesis of
healthy epithelial cells.
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Gene description MDA-MB-231 MCF-10a Gene description MDA-MB-231 MCF-10a
Ribosomal protein S27a 1.1 8.3 Jun oncogene 1.5 3.8
V-akt murine thymoma viral oncogene homolog 1 0.6 UP CD82 molecule ND ND
Angiopoietin 1 0.2 ND KiSS-1 metastasis-suppressor ND UP
Angiopoietin 2 0.9 ND Mitogen-activated protein kinase kinase 1 0.7 1.2
Apoptotic peptidase activating factor 1 0.3 ND Mitogen-activated protein kinase 14 DOWN ND
Ataxia telangiectasia mutated 0.8 ND Melanoma cell adhesion molecule 0.4 ND
BCL2-antagonist of cell death 0.7 ND Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse) DOWN ND
Brain-specific angiogenesis inhibitor 1 0.7 ND Met proto-oncogene (hepatocyte growth factor receptor) UP ND
BCL2-associated X protein 1.2 UP MHC class I polypeptide-related sequence A UP ND
B-cell CLL/lymphoma 2 6.1 UP Matrix metallopeptidase 1 (interstitial collagenase) 0.8 ND
BCL2-like 1 2.5 ND Matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) 0.4 1.5
Baculoviral IAP repeat-containing 5 (survivin) 1.3 2.9 Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) DOWN ND
Breast cancer 1, early onset 2.8 ND Metastasis associated 1 DOWN ND
Breast cancer 2, early onset 0.6 UP Metastasis associated 1 family, member 2 DOWN ND
Caspase 8, apoptosis-related cysteine peptidase 0.7 ND Metastasis suppressor 1 ND ND
Caspase 9, apoptosis-related cysteine peptidase 0.9 UP V-myc myelocytomatosis viral oncogene homolog (avian) ND UP
Cyclin D1 UP ND Neural cell adhesion molecule 1 ND ND
Cyclin E1 4.0 UP Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) 0.8 1.4
CD44 molecule (Indian blood group) 3.7 UP Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 1.1 1.0
Cell division cycle 25 homolog A (S. pombe) 1.3 4.1 Non-metastatic cells 1, protein (NM23A) expressed in 1.0 1.9
Cadherin 1, type 1, E-cadherin (epithelial) DOWN ND Non-metastatic cells 4, protein expressed in 0.4 0.7
Cyclin-dependent kinase 2 0.5 UP Platelet-derived growth factor alpha polypeptide DOWN ND
Cyclin-dependent kinase 4 1.1 2.4 Platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog) 0.3 ND
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 0.9 1.4 Phosphoinositide-3-kinase, catalytic, beta polypeptide UP UP
Cyclin-dependent kinase inhibitor 1B (p27, Kip1) UP ND Phosphoinositide-3-kinase, regulatory subunit 1 (alpha) ND 1.8
Cyclin-dependent kinase inhibitor 2A (melanoma, 
p16, inhibits CDK4) ND ND Plasminogen activator, urokinase 1.0 1.2
CASP8 and FADD-like apoptosis regulator ND ND Plasminogen activator, urokinase receptor 1.1 1.7
CHK2 checkpoint homolog (S. pombe) ND ND Pinin, desmosome associated protein 1.5 1.2
Collagen, type XVIII, alpha 1 1.7 ND Protein kinase, DNA-activated, catalytic polypeptide ND ND
Catenin (cadherin-associated protein), beta 1, 
88kDa DOWN ND
Phosphatase and tensin homolog (mutated in 
multiple advanced cancers 1) DOWN ND
E2F transcription factor 1 0.9 ND V-raf-1 murine leukemia viral oncogene homolog 1 DOWN ND
Epidermal growth factor (beta-urogastrone) 0.3 ND RAS p21 protein activator (GTPase activating protein) 1 ND ND
Epidermal growth factor receptor (erythroblastic 
leukemia viral (v-erb-b) oncogene homolog, avian) 2.6 4.6 Retinoblastoma 1 (including osteosarcoma) 2.4 2.6
V-erb-b2 erythroblastic leukemia viral oncogene
homolog 2, neuro/glioblastoma derived oncogene 
homolog (avian)
1.2 2.5 S100 calcium binding protein A4 0.9 0.9
V-Ets erythroblastosis virus E26 oncogene homolog 
2 (avian) 1.7 ND
Serpin peptidase inhibitor, clade B (ovalbumin), 
member 2 1.2 2.0
Fibroblast growth factor 2 (basic) ND ND Serpin peptidase inhibitor, clade B (ovalbumin), member 5 0.9 1.0
